After establishing the efficacy of PRK and SRB as potent inhibitor of mycobacterial growth, we tested their efficacy in combination with the standard‐of‐care anti‐TB drugs [rifampicin (R), isoniazid (H), and ethambutol (E)]. This evidence concerns the gene CCT4 and tuberculosis.